Samsung Biologics' 2.7 trillion won rights offering draws 96.8% subscription, nearing full take-up

Samsung Biologics' 2.7 trillion won rights offering has drawn a subscription rate of 96.8%, nearing full take-up, with the general public offering to begin on the 12th.

Detected & updated continuously · Source: Nebula